Companies Vir Biotechnology, Inc. and GlaxoSmithKline plc (GSK) announced the global extension to phase 3 of the COMET-ICE study, which evaluates the effectiveness of monoclonal antibodies – VIR-7831 for early treatment of COVID-19 in patients at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is the fully human monoclonal antibody against SARS-CoV-2, selected for […]